IDRA Stock Overview
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States.
Idera Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.48|
|52 Week High||US$1.71|
|52 Week Low||US$0.29|
|1 Month Change||-0.37%|
|3 Month Change||-0.68%|
|1 Year Change||-56.05%|
|3 Year Change||-81.40%|
|5 Year Change||-96.38%|
|Change since IPO||-99.99%|
Recent News & Updates
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|IDRA||US Biotechs||US Market|
Return vs Industry: IDRA underperformed the US Biotechs industry which returned -21.4% over the past year.
Return vs Market: IDRA underperformed the US Market which returned -11.5% over the past year.
|IDRA Average Weekly Movement||12.6%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: IDRA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IDRA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
|1989||13||Vinnie, Vin Milano||https://www.iderapharma.com|
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb.
Idera Pharmaceuticals Fundamentals Summary
|IDRA fundamental statistics|
Is IDRA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDRA income statement (TTM)|
|Cost of Revenue||US$9.25m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.32|
|Net Profit Margin||0.00%|
How did IDRA perform over the long term?See historical performance and comparison
Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IDRA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IDRA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: IDRA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IDRA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IDRA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IDRA is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (1.5x).
How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if IDRA's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if IDRA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if IDRA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if IDRA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IDRA's Return on Equity is forecast to be high in 3 years time
How has Idera Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDRA is currently unprofitable.
Growing Profit Margin: IDRA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IDRA is unprofitable, but has reduced losses over the past 5 years at a rate of 23.2% per year.
Accelerating Growth: Unable to compare IDRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: IDRA has a negative Return on Equity (-84.45%), as it is currently unprofitable.
How is Idera Pharmaceuticals's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IDRA's short term assets ($29.4M) exceed its short term liabilities ($3.8M).
Long Term Liabilities: IDRA's short term assets ($29.4M) exceed its long term liabilities ($494.0K).
Debt to Equity History and Analysis
Debt Level: IDRA is debt free.
Reducing Debt: IDRA has no debt compared to 5 years ago when its debt to equity ratio was 0.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IDRA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IDRA has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 6.3% each year.
What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IDRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IDRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IDRA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IDRA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IDRA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vinnie, Vin Milano (57 yo)
Mr. Vincent J. Milano, also known as Vinnie and Vin, has been an Independent Director of BioCryst Pharmaceuticals, Inc. since July 26, 2021. He has been an Independent Director at Aclaris Therapeutics, Inc...
CEO Compensation Analysis
Compensation vs Market: Vinnie, Vin's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD770.27K).
Compensation vs Earnings: Vinnie, Vin's compensation has been consistent with company performance over the past year.
Experienced Management: IDRA's management team is considered experienced (3.6 years average tenure).
Experienced Board: IDRA's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Idera Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Idera Pharmaceuticals, Inc.
- Ticker: IDRA
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$23.554m
- Shares outstanding: 52.97m
- Website: https://www.iderapharma.com
Number of Employees
- Idera Pharmaceuticals, Inc.
- 505 Eagleview Boulevard
- Suite 212
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.